Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rasschaert, Marika
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Recruiting	3	864	Europe, Canada, Japan, US, RoW	Dostarlimab, Placebo	GlaxoSmithKline	Neoplasms, Head and Neck	05/28	07/29
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC	Active, not recruiting	2	65	Europe, US, RoW	ISA101b, Cemiplimab	ISA Pharmaceuticals, Regeneron Pharmaceuticals	Squamous Cell Carcinoma of the Oropharynx	06/24	12/24
KEYNOTE-C34, NCT04811027 / 2021-000055-39: Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC Oct 2021 - Oct 2021: Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC	Active, not recruiting	2	171	Europe, US, RoW	eftilagimod alpha, IMP321, efti, eftilagimod alfa, pembrolizumab (KEYTRUDA®), MK-3475	Immutep S.A.S., Merck Sharp & Dohme LLC	HNSCC	03/24	03/25
HyperlynX, NCT06056310: Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN	Terminated	1	18	Europe, US, RoW	Xevinapant, Debio 1143, Cisplatin, intensity-modulated radiation therapy (IMRT)	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24